Maccura Biotechnology shareholder to trim stake for personal capital needs

Maccura Biotechnology announced today that Guo Lei, a shareholder holding over 5% of the company's shares, plans to reduce his stake. Guo Lei intends to sell up to 500,000 shares through centralized bidding, representing no more than 0.08% of the company's current total share capital. The sales are scheduled to occur over three months, commencing 15 trading days after the announcement date, from December 18, 2025, to March 17, 2026. The reason cited for the divestment is personal capital needs.

As of the announcement date, Guo Lei holds 30,324,906 shares, equating to 5.02% of the total share capital. A notable portion, 18,340,000 shares, or 60.48% of his total holdings (3.03% of the company's total share capital), are currently pledged. The shares originate from pre-IPO holdings, shares acquired through capital reserve conversion, and shares increased via centralized bidding after listing.

The company stated that this reduction plan aligns with relevant laws and regulations and is considered a normal shareholder activity. It is not expected to significantly impact Maccura Biotechnology's governance structure, equity structure, or future operations, nor will it lead to a change in control.